Suchergebnisse - "Roeker, Lindsey E"

PubPharm (56)

31

Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation

enthalten in: Blood advances | 2021

von Lahoud, O. | Devlin, S. | Maloy, M. | +15

32

Searching for a home : phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice

enthalten in: British journal of haematology | 2021

von Roeker, L. | Thompson, M. | Mato, A.

CommentOn: Br J Haematol. 2021 Jul;194(1):69-77. - PMID 34121184

33

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN) : a phase 1/2 study

enthalten in: Lancet (London, England) | 2021

von Mato, A. | Shah, N. | Jurczak, W. | +41

CommentIn: Lancet. 2021 Mar 6;397(10277):855-857. - PMID 33676615

34

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia

enthalten in: Haematologica | 2021

von Eyre, T. | Lamanna, N. | Roeker, L. | +27

35

Searching for a home : phosphoinositide 3‐kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice

enthalten in: British Journal of Haematology | 2021

von Roeker, L. | Thompson, M. | Mato, A.

36

Approaches for relapsed CLL after chemotherapy-free frontline regimens

enthalten in: Hematology. American Society of Hematology. Education Program | 2020

von Roeker, L. | Mato, A.

37

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

enthalten in: Leukemia | 2020

von Roeker, L. | Knorr, D. | Pessin, M. | +5

CommentIn: Leukemia. 2021 Jan;35(1):289-292. - PMID 33299142

38

Outcomes of COVID-19 in patients with CLL : a multicenter international experience

enthalten in: Blood | 2020

von Mato, A. | Roeker, L. | Lamanna, N. | +59

CommentIn: Blood. 2020 Sep 3;136(10):1115-1116. - PMID 32882019

39

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

enthalten in: Blood advances | 2020

von Roeker, L. | Dreger, P. | Brown, J. | +22

40

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Mato, A. | Roeker, L. | Jacobs, R. | +51

CommentIn: Clin Cancer Res. 2020 Jul 15;26(14):3501-3502. - PMID 32366672